Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical company Swedish Orphan International has taken over the assets of ViraNative, a biotech company based in Umea, Sweden.
Subscribe to our email newsletter
ViraNative filed for bankruptcy in September and Swedish Orphan International acquired the bankruptcy estate.
Through this takeover Swedish Orphan International has acquired the worldwide rights for the drug Multiferon, approved in Sweden for the treatment of malignant melanoma, and ensures future supply of the drug to patients across the world.
Swedish Orphan secures continued production and availability of Multiferon through the take over of the production facilities in Umea and also ensures that the approval process for broader use in Europe will be initiated.
Bo Jesper Hansen, CEO, Swedish Orphan International, said: “Multiferon is a unique product which potentially is lifesaving for a significant number of patients. The purpose of the acquisition is to secure future availability of this important treatment for patients all over the world.”